Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 2,500 shares of the company's stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $47.10, for a total transaction of $117,750.00. Following the completion of the sale, the senior vice president now directly owns 2,426 shares in the company, valued at $114,264.60. This represents a 50.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Mirum Pharmaceuticals Price Performance
Shares of MIRM opened at $44.50 on Friday. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.14 and a 12 month high of $48.89. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.09. The stock has a fifty day moving average price of $40.12 and a 200 day moving average price of $36.00. The company has a market cap of $2.14 billion, a P/E ratio of -22.03 and a beta of 1.16.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. During the same quarter in the prior year, the firm earned ($0.57) earnings per share. The company's quarterly revenue was up 89.4% on a year-over-year basis. On average, research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.81 earnings per share for the current year.
Institutional Investors Weigh In On Mirum Pharmaceuticals
Financial Prophecy
From Porter & Company | Ad
The Magnificent 7 could be in for a world of pain…
And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock.
The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on.
It’s called The Final Frontier.
Including the name of the #1 company to buy.
Several large investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Mirum Pharmaceuticals by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company's stock worth $67,000 after buying an additional 318 shares during the period. Amalgamated Bank raised its stake in Mirum Pharmaceuticals by 60.8% during the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company's stock valued at $46,000 after acquiring an additional 513 shares in the last quarter. Arizona State Retirement System boosted its position in Mirum Pharmaceuticals by 10.6% during the 2nd quarter. Arizona State Retirement System now owns 9,210 shares of the company's stock worth $315,000 after acquiring an additional 883 shares during the period. Quest Partners LLC grew its stake in shares of Mirum Pharmaceuticals by 7,513.3% in the second quarter. Quest Partners LLC now owns 1,142 shares of the company's stock worth $39,000 after purchasing an additional 1,127 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of Mirum Pharmaceuticals by 11.7% during the first quarter. Russell Investments Group Ltd. now owns 17,481 shares of the company's stock valued at $439,000 after purchasing an additional 1,825 shares during the period.
Analysts Set New Price Targets
MIRM has been the subject of several research analyst reports. Evercore ISI boosted their target price on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an "outperform" rating in a research report on Thursday, August 8th. Leerink Partners boosted their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an "outperform" rating in a report on Thursday, October 17th. HC Wainwright reaffirmed a "buy" rating and set a $66.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday. Citigroup lifted their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, Robert W. Baird upped their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an "outperform" rating in a research report on Wednesday. Ten equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $57.73.
Get Our Latest Stock Report on Mirum Pharmaceuticals
Mirum Pharmaceuticals Company Profile
(
Get Free Report)
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
